RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nathan J Bowen to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Nathan J Bowen has written about Xenograft Model Antitumor Assays.
Nathan J Bowen
Connection Strength
0.079
Xenograft Model Antitumor Assays
  1. Li X, Mamouni K, Zhao R, Bai L, Chen Y, Wu Y, Xie ZR, Sautto GA, Liu D, Bowen NJ, Danaher A, Li D, Cook N, Grayson S, Zhu J, Coleman IM, Nelson PS, Bao Q, Zhou J, Osunkoya AO, Kucuk O, Gera L, Wu D. Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer. Br J Cancer. 2025 Jun; 132(12):1188-1199.
    View in: PubMed
    Score: 0.052
  2. Sheng X, Bowen N, Wang Z. GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer. Mol Cancer. 2016 Mar 18; 15:25.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support